View in EDS HTML Full Text PDF Full Text

Enabling next-generation engineered TCR-T therapies based on high-throughput TCR discovery from diagnostic tumor biopsies.

Saved in:
Bibliographic Details
Title: Enabling next-generation engineered TCR-T therapies based on high-throughput TCR discovery from diagnostic tumor biopsies.
Authors: Kuilman T; Neogene Therapeutics, A member of the AstraZeneca Group, Amsterdam, The Netherlands. thomas.kuilman@astrazeneca.com., Schrikkema DS; Neogene Therapeutics, A member of the AstraZeneca Group, Amsterdam, The Netherlands., Gadiot J; Neogene Therapeutics, A member of the AstraZeneca Group, Amsterdam, The Netherlands., Gomez-Eerland R; Neogene Therapeutics, A member of the AstraZeneca Group, Amsterdam, The Netherlands., Bies L; Neogene Therapeutics, A member of the AstraZeneca Group, Amsterdam, The Netherlands., Walker J; Neogene Therapeutics, A member of the AstraZeneca Group, Amsterdam, The Netherlands., Spaapen RM; Neogene Therapeutics, A member of the AstraZeneca Group, Amsterdam, The Netherlands., Kok H; Neogene Therapeutics, A member of the AstraZeneca Group, Amsterdam, The Netherlands., Houg D; Neogene Therapeutics, A member of the AstraZeneca Group, Amsterdam, The Netherlands., Viyacheva M; Neogene Therapeutics, A member of the AstraZeneca Group, Amsterdam, The Netherlands., Claassen YB; Neogene Therapeutics, A member of the AstraZeneca Group, Amsterdam, The Netherlands., Saornil M; Neogene Therapeutics, A member of the AstraZeneca Group, Amsterdam, The Netherlands., Krijgsman O; Neogene Therapeutics, A member of the AstraZeneca Group, Amsterdam, The Netherlands., Stringer B; Neogene Therapeutics, A member of the AstraZeneca Group, Amsterdam, The Netherlands., Ding H; Neogene Therapeutics, A member of the AstraZeneca Group, Amsterdam, The Netherlands., Geleijnse A; Neogene Therapeutics, A member of the AstraZeneca Group, Amsterdam, The Netherlands., Meinema AC; Neogene Therapeutics, A member of the AstraZeneca Group, Amsterdam, The Netherlands., Weissbrich B; Neogene Therapeutics, A member of the AstraZeneca Group, Amsterdam, The Netherlands., Lancee M; Neogene Therapeutics, A member of the AstraZeneca Group, Amsterdam, The Netherlands., Engele CG; Neogene Therapeutics, A member of the AstraZeneca Group, Amsterdam, The Netherlands., Sabatino M; Neogene Therapeutics, A member of the AstraZeneca Group, Amsterdam, The Netherlands., Chen PL; Department of Pathology, Moffitt Cancer Center, Tampa, FL, USA.; Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA., Tsai KY; Department of Pathology, Moffitt Cancer Center, Tampa, FL, USA.; Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA., Mulé JJ; Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA.; Department of Immunology and Radiation Oncology Program, Moffitt Cancer Center, Tampa, FL, USA., Sondak VK; Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA., van den Bulk J; Neogene Therapeutics, A member of the AstraZeneca Group, Amsterdam, The Netherlands.; Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands., de Miranda NF; Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands., Jedema I; Division of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Haanen JG; Division of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Clinical Oncology, Leiden University Medical Center, Leiden, The Netherlands., van Heijst JWJ; Neogene Therapeutics, A member of the AstraZeneca Group, Amsterdam, The Netherlands., Schumacher TN; Division of Molecular Oncology & Immunology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands., Linnemann C; Neogene Therapeutics, A member of the AstraZeneca Group, Amsterdam, The Netherlands., Bendle GM; Neogene Therapeutics, A member of the AstraZeneca Group, Amsterdam, The Netherlands. gavin.bendle@astrazeneca.com.
Source: Nature communications [Nat Commun] 2025 Jan 14; Vol. 16 (1), pp. 649. Date of Electronic Publication: 2025 Jan 14.
Publication Type: Journal Article
Journal Info: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 39809767
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Enabling next-generation engineered TCR-T therapies based on high-throughput TCR discovery from diagnostic tumor biopsies.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Kuilman+T%22">Kuilman T</searchLink>; Neogene Therapeutics, A member of the AstraZeneca Group, Amsterdam, The Netherlands. thomas.kuilman@astrazeneca.com.<br /><searchLink fieldCode="AU" term="%22Schrikkema+DS%22">Schrikkema DS</searchLink>; Neogene Therapeutics, A member of the AstraZeneca Group, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Gadiot+J%22">Gadiot J</searchLink>; Neogene Therapeutics, A member of the AstraZeneca Group, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Gomez-Eerland+R%22">Gomez-Eerland R</searchLink>; Neogene Therapeutics, A member of the AstraZeneca Group, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Bies+L%22">Bies L</searchLink>; Neogene Therapeutics, A member of the AstraZeneca Group, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Walker+J%22">Walker J</searchLink>; Neogene Therapeutics, A member of the AstraZeneca Group, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Spaapen+RM%22">Spaapen RM</searchLink>; Neogene Therapeutics, A member of the AstraZeneca Group, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Kok+H%22">Kok H</searchLink>; Neogene Therapeutics, A member of the AstraZeneca Group, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Houg+D%22">Houg D</searchLink>; Neogene Therapeutics, A member of the AstraZeneca Group, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Viyacheva+M%22">Viyacheva M</searchLink>; Neogene Therapeutics, A member of the AstraZeneca Group, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Claassen+YB%22">Claassen YB</searchLink>; Neogene Therapeutics, A member of the AstraZeneca Group, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Saornil+M%22">Saornil M</searchLink>; Neogene Therapeutics, A member of the AstraZeneca Group, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Krijgsman+O%22">Krijgsman O</searchLink>; Neogene Therapeutics, A member of the AstraZeneca Group, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Stringer+B%22">Stringer B</searchLink>; Neogene Therapeutics, A member of the AstraZeneca Group, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Ding+H%22">Ding H</searchLink>; Neogene Therapeutics, A member of the AstraZeneca Group, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Geleijnse+A%22">Geleijnse A</searchLink>; Neogene Therapeutics, A member of the AstraZeneca Group, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Meinema+AC%22">Meinema AC</searchLink>; Neogene Therapeutics, A member of the AstraZeneca Group, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Weissbrich+B%22">Weissbrich B</searchLink>; Neogene Therapeutics, A member of the AstraZeneca Group, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Lancee+M%22">Lancee M</searchLink>; Neogene Therapeutics, A member of the AstraZeneca Group, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Engele+CG%22">Engele CG</searchLink>; Neogene Therapeutics, A member of the AstraZeneca Group, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Sabatino+M%22">Sabatino M</searchLink>; Neogene Therapeutics, A member of the AstraZeneca Group, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Chen+PL%22">Chen PL</searchLink>; Department of Pathology, Moffitt Cancer Center, Tampa, FL, USA.; Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA.<br /><searchLink fieldCode="AU" term="%22Tsai+KY%22">Tsai KY</searchLink>; Department of Pathology, Moffitt Cancer Center, Tampa, FL, USA.; Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA.<br /><searchLink fieldCode="AU" term="%22Mulé+JJ%22">Mulé JJ</searchLink>; Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA.; Department of Immunology and Radiation Oncology Program, Moffitt Cancer Center, Tampa, FL, USA.<br /><searchLink fieldCode="AU" term="%22Sondak+VK%22">Sondak VK</searchLink>; Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA.<br /><searchLink fieldCode="AU" term="%22van+den+Bulk+J%22">van den Bulk J</searchLink>; Neogene Therapeutics, A member of the AstraZeneca Group, Amsterdam, The Netherlands.; Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands.<br /><searchLink fieldCode="AU" term="%22de+Miranda+NF%22">de Miranda NF</searchLink>; Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Jedema+I%22">Jedema I</searchLink>; Division of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Haanen+JG%22">Haanen JG</searchLink>; Division of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Clinical Oncology, Leiden University Medical Center, Leiden, The Netherlands.<br /><searchLink fieldCode="AU" term="%22van+Heijst+JWJ%22">van Heijst JWJ</searchLink>; Neogene Therapeutics, A member of the AstraZeneca Group, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Schumacher+TN%22">Schumacher TN</searchLink>; Division of Molecular Oncology & Immunology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Linnemann+C%22">Linnemann C</searchLink>; Neogene Therapeutics, A member of the AstraZeneca Group, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Bendle+GM%22">Bendle GM</searchLink>; Neogene Therapeutics, A member of the AstraZeneca Group, Amsterdam, The Netherlands. gavin.bendle@astrazeneca.com.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101528555%22">Nature communications</searchLink> [Nat Commun] 2025 Jan 14; Vol. 16 (1), pp. 649. <i>Date of Electronic Publication: </i>2025 Jan 14.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Nature+Pub%2E+Group%22">Nature Pub. Group </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101528555 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2041-1723 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2220411723%22">20411723 </searchLink><i>NLM ISO Abbreviation: </i>Nat Commun <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=39809767
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1038/s41467-024-55420-6
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 649
    Titles:
      – TitleFull: Enabling next-generation engineered TCR-T therapies based on high-throughput TCR discovery from diagnostic tumor biopsies.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Kuilman T
      – PersonEntity:
          Name:
            NameFull: Schrikkema DS
      – PersonEntity:
          Name:
            NameFull: Gadiot J
      – PersonEntity:
          Name:
            NameFull: Gomez-Eerland R
      – PersonEntity:
          Name:
            NameFull: Bies L
      – PersonEntity:
          Name:
            NameFull: Walker J
      – PersonEntity:
          Name:
            NameFull: Spaapen RM
      – PersonEntity:
          Name:
            NameFull: Kok H
      – PersonEntity:
          Name:
            NameFull: Houg D
      – PersonEntity:
          Name:
            NameFull: Viyacheva M
      – PersonEntity:
          Name:
            NameFull: Claassen YB
      – PersonEntity:
          Name:
            NameFull: Saornil M
      – PersonEntity:
          Name:
            NameFull: Krijgsman O
      – PersonEntity:
          Name:
            NameFull: Stringer B
      – PersonEntity:
          Name:
            NameFull: Ding H
      – PersonEntity:
          Name:
            NameFull: Geleijnse A
      – PersonEntity:
          Name:
            NameFull: Meinema AC
      – PersonEntity:
          Name:
            NameFull: Weissbrich B
      – PersonEntity:
          Name:
            NameFull: Lancee M
      – PersonEntity:
          Name:
            NameFull: Engele CG
      – PersonEntity:
          Name:
            NameFull: Sabatino M
      – PersonEntity:
          Name:
            NameFull: Chen PL
      – PersonEntity:
          Name:
            NameFull: Tsai KY
      – PersonEntity:
          Name:
            NameFull: Mulé JJ
      – PersonEntity:
          Name:
            NameFull: Sondak VK
      – PersonEntity:
          Name:
            NameFull: van den Bulk J
      – PersonEntity:
          Name:
            NameFull: de Miranda NF
      – PersonEntity:
          Name:
            NameFull: Jedema I
      – PersonEntity:
          Name:
            NameFull: Haanen JG
      – PersonEntity:
          Name:
            NameFull: van Heijst JWJ
      – PersonEntity:
          Name:
            NameFull: Schumacher TN
      – PersonEntity:
          Name:
            NameFull: Linnemann C
      – PersonEntity:
          Name:
            NameFull: Bendle GM
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 14
              M: 01
              Text: 2025 Jan 14
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 2041-1723
          Numbering:
            – Type: volume
              Value: 16
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: Nature communications
              Type: main
ResultId 1